AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02274675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
Study NCT02422108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Study NCT02796911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenograft
Description: group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
Study NCT02796911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioactive glass
Description: group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
Study NCT01480830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Endoscopic Imaging (MEI) colonoscopy
Description: Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
Study NCT02160808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion
Study NCT02160808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04443452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Function Assessment (B)
Description: The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
Study NCT04443452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Balance Assessment
Description: Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
Study NCT03636451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
Study NCT03636451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20cc 1% lidocaine with 2 units of vasopressin paracervical block
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
Study NCT01043406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seizure Advisory System
Description: Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
Study NCT04194502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transesophageal echocardiogram (TEE)
Description: All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
Study NCT04570644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Description: Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study.
Study NCT02776696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Hybrid Closed Loop System
Study NCT02776696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop System
Study NCT01317134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoPAT measurement
Description: EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
Study NCT01317134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Test
Description: It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
Study NCT04747106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
Study NCT03425890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURE program
Description: SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
Study NCT04763213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
Study NCT04763213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
Study NCT05001906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
Study NCT01496209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endomyocardial injections of allogeneic Human CSps
Description: NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
Study NCT01496209 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Endomyocardial injections of vehicle only.
Description: NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
Study NCT03627962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze-directed oculomotor training
Description: Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell > 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session
Study NCT03917706 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
Study NCT02814305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial
Description: Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
Study NCT02814305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
Study NCT00159744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine
Description: Asenapine, 3 weeks
Study NCT00159744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 3 weeks
Study NCT00159744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 3 weeks
Study NCT02567344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
Study NCT02567344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
Study NCT01473251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: 1.25 mg monthly for 4 months
Study NCT01473251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.5 mg monthly for 4 months
Study NCT02388529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study NCT02388529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study NCT02388529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study NCT02388529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study NCT02187094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499
Study NCT02187094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01294735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
Study NCT01294735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
Study NCT01102153 — intervention group
Intervention type: DEVICE
Intervention: Coolgard
Description: invasive cooling via femoral ICY-catheter
Study NCT01102153 — intervention group
Intervention type: DEVICE
Intervention: ArcticSun
Description: non-invasive surface cooling by saline-cooled thermo-vest
Study NCT02560688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: 20 mg single 12-hour intravenous infusion
Study NCT02560688 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
Study NCT03636022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR System
Description: Use of virtual reality to deliver exposure therapy
Study NCT03636022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Use of conventional delivery of exposure therapy
Study NCT05640596 — intervention group
Intervention type: DRUG
Intervention: Betamethasone
Study NCT02560688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
Study NCT00851942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synacthen (Tetracosactrin)
Description: IV injection of 250 micrograms of Synacthen in 1ml
Study NCT01492387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of antibiotic therapy
Description: Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
Study NCT01833832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
Study NCT01833832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
Study NCT01833832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: sodium thiosulfate will be given to limit the toxicity of cisplatin
Study NCT03517358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service of care
Description: Subjects will be receiving care from case management or clinical pharmacy.
Study NCT00642759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
Study NCT00479141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV skills training
Description: Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
Study NCT00479141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leaders training
Description: Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
Study NCT02057718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001 (Maralixibat)
Description: LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
Study NCT02578212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02578212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: 2 doses administered intramuscularly
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: 2 doses administered intramuscularly
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: 1 dose administered subcutaneously
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: 1 dose administered subcutaneously
Study NCT01599754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5 mg twice daily
Study NCT01599754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT02938065 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
Study NCT02938065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2% milk
Description: 16 participants will drink 10 ounces of 2% milk
Study NCT02938065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: apple juice
Description: 16 participants will drink 10 ounces of apple juice
Study NCT02938065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ensure clear
Description: 16 participants will drink 10 ounces of ensure clear
Study NCT02924506 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mobi-C prothesis
Description: Mobi-C Prothesis, LDR Medical (company)
Study NCT02924506 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ProDisc-C prothesis
Description: ProDisc-C prothesis, Vivo Depuy Synthes (company)
Study NCT01350037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
Study NCT01350037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
Study NCT03152136 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cala ONE device
Description: The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
Study NCT03152136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala ONE device
Description: The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
Study NCT02882399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortystrap
Study NCT00660868 — intervention group
Intervention type: DRUG
Intervention: Pentoxifylline retard 400mg
Description: Agapurin retard 400mg 3/day per os for 3 weeks
Study NCT03577886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-6114
Description: CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
Study NCT03577886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Diluent oral solution
Study NCT01774630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 300 mg/twice a day
Study NCT04139031 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonographic measurement of corrected flow time in carotid artery
Description: Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
Study NCT00642759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
Study NCT00642759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT04614337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily
Study NCT04614337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH Norditropin® pen (34 µg/kg)
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study NCT04139408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Pulmonary Surgical Marker
Description: The subjects will undergo Marker placement procedure, within 24h before VATS.
Study NCT00561379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP+RITUXIMAB
Description: CHOP-14- Rituximab x 8 courses